Tolerance Bio Emerges from Steal with $17.2 Million to Advance Therapies for Immune illnesses nextdigitalhealth.com

A leading biotechnology startup pioneering a novel approach for extending healthspan by manipulating the functions of the thymus, Tolerance Bio, Inc., has secured $17.2 million in an oversubscribed seed investment round to advance the pioneering concept of developing medications for rare diseases.

Founded in 2023 by Francisco Leon, Ph.D, the company focuses on extending the human health span by restoring, manipulating, and preserving the functions of the thymus, which is always critical in the regulation of immune tolerance.